Risk factors and therapy strategies of a first line treatment failure after invasive fungal infections
- Conditions
- invasive fungal diseases
- Registration Number
- DRKS00024735
- Lead Sponsor
- niversitätsklinikum Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 180
Since this is a purely retrospective data analysis, there is no recruitment of patients; rather, patient records are screened to identify suitable records for analysis. The data sets are drawn from the files of patients who suffered from invasive candidiasis [candidemia, intra-abdominal candidiasis (IAC)], invasive aspergillosis (IA), invasive pulmonary aspergillosis (IPA) or any other invasive infection between January 2006 and December 2016 with rare fungal species suffered. In addition, patients should be included who only have a positive galactomannan test (Aspergillus-Ag positive) or a culture of Aspergillus spp. and for whom aspiration (inhalation of food components, e.g. through vomiting) was suspected.
With regard to microbiological data: Only information on microbiological data from existing patient files is collected. In the absence of information, no additional samples will be obtained for the study. There is no patient contact.
no specific exclusion criteria
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalance of invasive fungal diseases in ICU patients
- Secondary Outcome Measures
Name Time Method Incidence of primary-, secondary- or salvage therapies